Duke University School of Medicine, Durham, NC, USA.
Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620929092. doi: 10.1177/1076029620929092.
Bleeding and thrombosis in critically ill infants and children is a vexing clinical problem. Despite the relatively low incidence of bleeding and thrombosis in the overall pediatric population relative to adults, these critically ill children face unique challenges to hemostasis due to extreme physiologic derangements, exposure of blood to foreign surfaces and membranes, and major vascular endothelial injury or disruption. Caring for pediatric patients on extracorporeal support, recovering from solid organ transplant or invasive surgery, and after major trauma is often complicated by major bleeding or clotting events. As our ability to care for the youngest and sickest of these children increases, the gaps in our understanding of the clinical implications of developmental hemostasis have become increasingly important. We review the current understanding of the development and function of the hemostatic system, including the complex and overlapping interactions of coagulation proteins, platelets, fibrinolysis, and immune mediators from the neonatal period through early childhood and to young adulthood. We then examine scenarios in which our ability to effectively measure and treat coagulation derangements in pediatric patients is limited. In these clinical situations, adult therapies are often extrapolated for use in children without taking age-related differences in pediatric hemostasis into account, leaving clinicians confused and impacting patient outcomes. We discuss the limitations of current coagulation testing in pediatric patients before turning to emerging ideas in the measurement and management of pediatric bleeding and thrombosis. Finally, we highlight opportunities for future research which take into account this developing balance of bleeding and thrombosis in our youngest patients.
危重病儿的出血和血栓形成是一个令人困扰的临床问题。尽管与成人相比,出血和血栓形成在儿科人群中的发病率相对较低,但这些危重病儿由于极度的生理失调、血液与异物表面和膜的接触以及主要血管内皮损伤或破坏,面临着独特的止血挑战。在体外支持下护理儿科患者、从实体器官移植或侵入性手术中恢复以及经历重大创伤后,常常会出现严重出血或凝血事件。随着我们照顾这些最年幼和最病重的患儿的能力不断提高,我们对发育性止血的临床意义的理解差距变得越来越重要。我们回顾了对止血系统发育和功能的现有认识,包括从新生儿期到幼儿期再到成年早期,凝血蛋白、血小板、纤维蛋白溶解和免疫介质之间复杂且重叠的相互作用。然后,我们检查了我们有效测量和治疗儿科患者凝血紊乱的能力受到限制的情况。在这些临床情况下,通常不考虑儿科止血方面的年龄相关差异,而是从成年人那里推断出治疗方法来治疗儿童,这让临床医生感到困惑并影响了患者的治疗结果。在转向儿科出血和血栓形成的测量和管理中的新观点之前,我们讨论了当前在儿科患者中进行凝血检测的局限性。最后,我们强调了未来研究的机会,这些研究考虑到了我们最年幼的患者中出血和血栓形成之间这种不断发展的平衡。